{"protocolSection":{"identificationModule":{"nctId":"NCT02273700","orgStudyIdInfo":{"id":"LOCAL/2014/GL-01"},"secondaryIdInfos":[{"id":"2014-A00516-41","type":"OTHER","domain":"RCB number"}],"organization":{"fullName":"Centre Hospitalier Universitaire de Nīmes","class":"OTHER"},"briefTitle":"Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention","officialTitle":"Evaluation of Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention in Patients With Atrial Fibrillation","acronym":"Naco_Nîmes"},"statusModule":{"statusVerifiedDate":"2016-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11"},"primaryCompletionDateStruct":{"date":"2016-01","type":"ACTUAL"},"completionDateStruct":{"date":"2016-01","type":"ACTUAL"},"studyFirstSubmitDate":"2014-10-22","studyFirstSubmitQcDate":"2014-10-22","studyFirstPostDateStruct":{"date":"2014-10-24","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-08-23","lastUpdatePostDateStruct":{"date":"2016-08-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Centre Hospitalier Universitaire de Nīmes","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients with non-valvular atrial fibrillation to better understand the mechanisms of action of these molecules and perform exploratory analyses concerning proteins whose concentrations change after starting treatment."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Xarelto®","protein/peptide profiles"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":5,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"the Study Population","description":"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.\n\nIntervention: Rivaroxaban","interventionNames":["Drug: Rivaroxaban"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban","description":"Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.","armGroupLabels":["the Study Population"],"otherNames":["(Xarelto®)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The percent change in plasma protein/peptide profiles after one month of treatment versus before treatment","timeFrame":"1 month (between days 28 to 35) versus baseline (day 0)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient was correctly informed about the study, its implementation, objectives, associated restrictions and patient rights\n* The patient must have given his/her informed and signed consent\n* The patient must be insured or beneficiary of a health insurance plan\n* The patient is available for 1 month of follow-up\n* The patient has non-valvular atrial fibrillation that was diagnosed within the last 3 months. Documentation of atrial fibrillation by a 12-lead ECG, an ECG rhythm strip, atrial fibrillation episode lasting at least 30 seconds.\n* The patient has a CHA2-DS2-VASc score = 1, that is to say the presence of at least one of the following risk factors: (1) congestive heart failure or moderate to severe systolic dysfunction of the left ventricle; (2) history of systolic blood pressure\\> 160 mmHg; (3) diabetes; (4) history of ischemic stroke or systemic embolism; (5) vascular disease (myocardial infarction, arterial disease); (6) age \\> 65 years; (7) female.\n* The patient will start Rivaroxaban (Xarelto®) at the Nîmes University Hospital\n\nExclusion Criteria:\n\n* The patient is participating in another interventional study\n* The patient has participated in another interventional study within the past three months\n* The patient is in an exclusion period determined by a previous study\n* The patient is under judicial protection, under tutorship or curatorship\n* The patient refuses to sign the consent\n* It is impossible to correctly inform the patient\n* The patient is pregnant, parturient, or breastfeeding\n* Presence of a mechanical heart valve or valve disease\n* Patient who recieved another new direct oral anticoagulant other than Xarelto® in the previous three months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Géraldine Lavigne-Lissalde, MD","affiliation":"Centre Hospitalier Universitaire de Nîmes","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"CHRU de Nîmes - Hôpital Universitaire Carémeau","city":"Nîmes Cedex 09","zip":"30029","country":"France","geoPoint":{"lat":43.83333,"lon":4.35}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M9271","name":"Heparin, Low-Molecular-Weight","relevance":"LOW"},{"id":"M19843","name":"Dalteparin","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}